There is no specific treatment for diseases caused by most of the emerging viruses. COVID-19 pandemic has helped us to evolve the proof of concept of monoclonal antibodies (mAbs) as an early stage treatment strategy to prevent complications. Monoclonal antibodies are highly specific to the viruses against which they are designed and efficiently neutralize their infectivity if designed and selected carefully. With modern genetic engineering and recombinant DNA technologies, it is possible to synthesize a gene and express the protein from it by advanced laboratories that have expertise in the process. This helps us to make immunogenic proteins that generate protective antibodies even against pathogens such as Ebola and Marburg viruses that are not yet reported in India, but threatens for a future emergence. Once this is done, the protein can be used for animal immunization to generate monoclonal antibodies. Such antibodies can be used for diagnostic as well as therapeutic purposes. Use of transgenic mice that are humanized will support the development of monoclonal antibodies that have therapeutic potential. In our flagship program envisaged for a three-year duration, we aim to establish these capabilities systematically so that we can develop high quality mAbs against Kysanur Forest Disease, Nipah, Ebola and Marburg disease viruses.